Pfizer is looking to newer products and acquisitions to offset a declining Covid business.

The decisions by Pfizer and Merck to share their COVID-19 drug patents stands in stark contrast to the refusal of Pfizer and other vaccine-makers to release their vaccine recipes

Pfizer is also demonstrating that its commercial portfolio can flourish beyond the historically mammoth sales of its COVID-19 vaccine and antiviral, the Citi team said, noting that the company’s crop of recent launches and acquired products—including Padcev,

Pfizer said Tuesday it signed a licensing agreement to allow broader global access to its experimental COVID-19 pill. The agreement with the Medicines Patent Pool, a United Nations-backed public health organization, would allow generic manufacturers to ...

NEW YORK -- When Laura Martin tested positive for COVID-19 last month during an extended stay in California, she was prescribed Paxlovid, the highly touted antiviral drug created by Pfizer. Just one day after her diagnosis, she started her five-day course ...

New England Journal of Medicine lets Anthony Fauci and his onetime deputy play down results in editorial alongside study from U.K., Canada trials. Critics suspect profit motive played role in long-delayed publication.

CHICAGO -- Pfizer has begun a Phase 2 and 3 clinical trial of its COVID-19 antiviral treatment, Paxlovid, in children ages 6 to 17, the company said Wednesday in a news release. The study will evaluate the safety and efficacy of the treatment in children ...